Trials / Completed
CompletedNCT02559687
Study of Pembrolizumab (MK-3475) in Previously-Treated Participants With Advanced Carcinoma of the Esophagus or Esophagogastric Junction (MK-3475-180/KEYNOTE-180)
A Phase II Study of Pembrolizumab Monotherapy in Third Line Previously Treated Subjects With Advanced/Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus or Advanced/Metastatic Siewert Type I Adenocarcinoma of the Esophagogastric Junction (KEYNOTE-180)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 121 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In this study participants with advanced/metastatic adenocarcinoma of the esophagus (EAC), squamous cell carcinoma of the esophagus (ESCC), or advanced/metastatic Siewert type I adenocarcinoma of the esophagogastric junction (EGJ), who had been previously treated with two standard therapies, will be treated with pembrolizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | pembrolizumab | IV Q3W |
Timeline
- Start date
- 2015-12-02
- Primary completion
- 2018-07-30
- Completion
- 2021-10-29
- First posted
- 2015-09-24
- Last updated
- 2022-09-14
- Results posted
- 2019-07-17
Source: ClinicalTrials.gov record NCT02559687. Inclusion in this directory is not an endorsement.